REGENERON PHARMACEUTICALS, INC. (REGN) — Q4 2025 13F-HR

← REGENERON PHARMACEUTICALS, INC. (REGN)

Q4 2025 · 13F-HR

REGENERON PHARMACEUTICALS, INC. (REGN)holdings as filed

Filed 2026-02-06 · accession 0001104659-26-011601

$33.8M

Reported value

Positions

2025-12-31

Period end

View analyzed profile →PRO

The Brief · REGENERON PHARMACEUTICALS, INC. (REGN) · Q4 2025

AI · grounded in 13F

REGENERON PHARMACEUTICALS, INC. (REGN) closed its position in Alnylam Pharmaceuticals, Inc. ALNY, reducing its holdings by $634.89M. The fund also exited its position in Adverum Biotechnologies, Inc. AVU0, a move totaling $819,518. Additionally, the fund trimmed its stake in Adicet Bio, Inc. TORCEUR by 93.75%.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
45826J105	NTLA	Intellia Therapeutics, Inc.	$33.3M	98.5%	3,702,995	Common	SOLE
007002108	TORCEUR	Adicet Bio, Inc.	$509,503	1.51%	60,511	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.